(Q38958363)

8 September 2017

1 reference

title

Treating hyperphosphatemia - current and advancing drugs (English)

1 reference

8 September 2017

Markus Ketteler

1

1 reference

8 September 2017

Orfeas Liangos

series ordinal

2

1 reference

8 September 2017

Patrick H Biggar

series ordinal

3

1 reference

8 September 2017

language of work or name

English

0 references

publication date

16 August 2016

1 reference

Expert Opinion on Pharmacotherapy

8 September 2017

published in

1 reference

8 September 2017

volume

17

1 reference

8 September 2017

issue

14

1 reference

8 September 2017

page(s)

1873-1879

1 reference

Prevalence of chronic kidney disease in population-based studies: systematic review

8 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1220538

Arterial calcification in chronic kidney disease: key roles for calcium and phosphate

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1220538

Dietary phosphorus acutely impairs endothelial function

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1220538

Mineral metabolism, mortality, and morbidity in maintenance hemodialysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1220538

Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1220538

Sodium-dependent phosphate cotransporters: lessons from gene knockout and mutation studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1220538

Forging forward with 10 burning questions on FGF23 in kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1220538

Uremia induces the osteoblast differentiation factor Cbfa1 in human blood vessels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1220538

Chronic mineral dysregulation promotes vascular smooth muscle cell adaptation and extracellular matrix calcification.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1220538

Is controlling phosphorus by decreasing dietary protein intake beneficial or harmful in persons with chronic kidney disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1220538

Vegetarian compared with meat dietary protein source and phosphorus homeostasis in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1220538

Effects of frequent hemodialysis on measures of CKD mineral and bone disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1220538

Phosphate binder use and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS): evaluation of possible confounding by nutritional status

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1220538

Phosphorus binders and survival on hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1220538

Oral calcium carbonate affects calcium but not phosphorus balance in stage 3-4 chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1220538

Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1220538

Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1220538

Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1220538

Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1220538

Sevelamer versus calcium carbonate in incident hemodialysis patients: results of an open-label 24-month randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1220538

Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1220538

Serological cardiovascular and mortality risk predictors in dialysis patients receiving sevelamer: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1220538

Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1220538

Effect of MCI-196 on serum phosphate and cholesterol levels in haemodialysis patients with hyperphosphataemia: a double-blind, randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1220538

A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1220538

Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1220538

Attenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in haemodialysis: A pilot randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1220538

Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1220538

Magnesium and outcomes in patients with chronic kidney disease: focus on vascular calcification, atherosclerosis and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1220538

Preclinical Pharmacokinetics, Pharmacodynamics and Safety of Sucroferric Oxyhydroxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1220538

Drug-drug interactions between sucroferric oxyhydroxide and losartan, furosemide, omeprazole, digoxin and warfarin in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1220538

Randomized clinical trial of the iron-based phosphate binder PA21 in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1220538

A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1220538

Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1220538

Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1220538

Ferric citrate controls phosphorus and delivers iron in patients on dialysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1220538

Ferric Citrate Reduces Intravenous Iron and Erythropoiesis-Stimulating Agent Use in ESRD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1220538

Effect of oral ferric citrate on serum phosphorus in hemodialysis patients: multicenter, randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1220538

A randomized trial of JTT-751 versus sevelamer hydrochloride in patients on hemodialysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1220538

Phosphate transporters: a tale of two solute carrier families.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1220538

Regulation of rat intestinal Na-dependent phosphate transporters by dietary phosphate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1220538

Hypophosphatemic effect of niacin in patients without renal failure: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1220538

Pharmacologic inhibition of intestinal sodium uptake: a gut centric approach to sodium management

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1220538

New pharmacological treatment options for irritable bowel syndrome with constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1220538

Gastrointestinal Inhibition of Sodium-Hydrogen Exchanger 3 Reduces Phosphorus Absorption and Protects against Vascular Calcification in CKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1220538

The contribution of chronic kidney disease to the global burden of major noncommunicable diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1220538

Calcium carbonate, but not sevelamer, is associated with better outcomes in hemodialysis patients: results from the French ARNOS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1220538

Mortality in kidney disease patients treated with phosphate binders: a randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1220538

Use of phosphate-binding agents is associated with a lower risk of mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1220538

10.1080/14656566.2016.1220538

21 January 2018

Identifiers

DOI

1 reference

8 September 2017

1 reference